Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$8.23 USD

8.23
100,362

+0.16 (1.98%)

Updated Jun 5, 2024 04:00 PM ET

After-Market: $8.23 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (141 out of 248)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Why Is Inogen (INGN) Down 7.9% Since Last Earnings Report?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inogen (INGN) Q3 Earnings Beat, 2018 Revenue Guidance Up

Inogen (INGN) gains from solid direct-to-consumer revenues in Q3; 2018 view up.

Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Inogen (INGN) Outperforming Other Medical Stocks This Year?

Is (INGN) Outperforming Other Medical Stocks This Year?

Inogen (INGN) Surpasses Q3 Earnings and Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of 40.38% and 4.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Panel Of Zacks Experts headshot

Top Stock Picks for the Week of November 5th

Two Companies Outperforming Their Industries.

Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?

Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.

Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips

Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.

Inogen (INGN) Gains But Lags Market: What You Should Know

Inogen (INGN) closed the most recent trading day at $192.30, moving +0.6% from the previous trading session.

NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark

NuVasive (NUVA) registers balanced growth across its couple of business wings.

Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance

The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.

Inogen (INGN) Reports Next Week: Wall Street Expects Earnings Growth

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y

Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.

Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises

Zacks.com featured highlights include: ABIOMED, Inogen, Turtle Beach, MCBC and Rush Enterprises

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.

Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates

Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.

Varian Medical (VAR) Jumps: Stock Rises 7.7%

Varian Medical (VAR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Pick 5 Profitable Stocks With Alluring Net Income Ratio

Investors always focus on companies that have a high level of profitability irrespective of the current market scenario.

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4

Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.

Is Inogen (INGN) Stock Outpacing Its Medical Peers This Year?

Is (INGN) Outperforming Other Medical Stocks This Year?

Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3

Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.

Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues

Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.

Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed

Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.

Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com

Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com